Standard-Dose Intradermal Influenza Vaccine Elicits Cellular Immune Responses Similar to Those of Intramuscular Vaccine in Men With and Those Without HIV Infection.

Autor:	Amoah S; Battelle Memorial Institute, Atlanta, Georgia.; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Mishina M; Battelle Memorial Institute, Atlanta, Georgia.; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Praphasiri P; Influenza Program, Bangkok, Thailand., Cao W; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Kim JH; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Liepkalns JS; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Guo Z; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Carney PJ; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Chang JC; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Fernandez S; Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand., Garg S; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Beacham L; Battelle Memorial Institute, Atlanta, Georgia.; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Holtz TH; Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.; HIV/STD Research Program, Thailand Ministry of Public Health-CDC Collaboration, Nonthaburi, Bangkok, Thailand., Curlin ME; Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand., Dawood F; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Olsen SJ; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Gangappa S; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Stevens J; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia., Sambhara S; Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2019 Jul 31; Vol. 220 (5), pp. 743-751.
DOI:	10.1093/infdis/jiz205
Abstrakt:	Background: Human immunodeficiency virus (HIV)-infected persons are at a higher risk of severe influenza. Although we have shown that a standard-dose intradermal influenza vaccine versus a standard-dose intramuscular influenza vaccine does not result in differences in hemagglutination-inhibition titers in this population, a comprehensive examination of cell-mediated immune responses remains lacking. Methods: Serological, antigen-specific B-cell, and interleukin 2-, interferon γ-, and tumor necrosis factor α-secreting T-cell responses were assessed in 79 HIV-infected men and 79 HIV-uninfected men. Results: The route of vaccination did not affect the immunoglobulin A and immunoglobulin G (IgG) plasmablast or memory B-cell response, although these were severely impaired in the group with a CD4+ T-cell count of <200 cells/μL. The frequencies of IgG memory B cells measured on day 28 after vaccination were highest in the HIV-uninfected group, followed by the group with a CD4+ T-cell count of ≥200 cells/μL and the group with a CD4+ T-cell count of <200 cells/μL. The route of vaccination did not affect the CD4+ or CD8+ T-cell responses measured at various times after vaccination. Conclusions: The route of vaccination had no effect on antibody responses, antibody avidity, T-cell responses, or B-cell responses in HIV-infected or HIV-uninfected subjects. With the serological and cellular immune responses to influenza vaccination being impaired in HIV-infected individuals with a CD4+ T-cell count of <200 cells/μL, passive immunization strategies need to be explored to protect this population. Clinical Trials Registration: NCT01538940. (Published by Oxford University Press for the Infectious Diseases Society of America 2019.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu